peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

Exendin-4 GLP-1 receptor agonist · 39 amino acids

Exenatide

/ex-EN-a-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Byetta

Twice-daily subcutaneous injection

Adjunct to diet and exercise in type 2 diabetes.

Find official label ↗
02

Bydureon BCise

Weekly extended-release injection

Type 2 diabetes; formulation-specific administration and warnings.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Activates GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon, slowing gastric emptying, and reducing food intake.Mechanism source
Labeled-use boundary
Immediate- and extended-release products are not interchangeable dosing formats.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Who should avoid it

  • Serious hypersensitivity
  • Product-specific renal and thrombocytopenia restrictions must be checked
Contraindications

More common effects

  • Nausea
  • Hypoglycemia with selected therapies
  • Vomiting
  • Diarrhea
  • Headache
  • Dyspepsia
Adverse reactions

Important serious risks

  • Acute pancreatitis
  • Acute kidney injury
  • Severe gastrointestinal disease
  • Immunogenicity
  • Injection-site reactions for extended-release products
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

Formulation changes the profile

Immediate-release and microsphere extended-release products produce different exposure patterns.

Supporting source
Evidence form
Clinical pharmacology
Keep in view
One product's instructions cannot substitute for another's.
02

Glycemic efficacy

Randomized diabetes trials measured A1C and related metabolic endpoints.

Supporting source
Evidence form
Randomized trials
Keep in view
Use is population- and background-therapy-specific.
03

Renal safety context

Label warnings reflect renal clearance and reported kidney injury.

Supporting source
Evidence form
Label and pharmacology
Keep in view
Individual risk requires clinical assessment.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Byetta prescribing information

    Current DailyMed label for immediate-release exenatide.

    Open source ↗
  2. 02Literature index
    Every PubMed result for exenatide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for exenatide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    exenatide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗